

Mark G Ward

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3755353/publications.pdf>

Version: 2024-02-01

35
papers

684
citations

758635

12
h-index

552369

26
g-index

35
all docs

35
docs citations

35
times ranked

955
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months. <i>Digestive Diseases and Sciences</i> , 2022, 67, 259-262. | 1.1 | 4 |
| 2 | Effects of fiber intake on intestinal pH, transit, and predicted oral mesalamine delivery in patients with ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1580-1589. | 1.4 | 9 |
| 3 | Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 990-998. | 1.4 | 5 |
| 4 | A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1909-1918. | 0.9 | 9 |
| 5 | Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure "out of sight but not out of mind. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1317-1318. | 1.9 | 1 |
| 6 | SARS-CoV-2 vaccination in patients with inflammatory bowel disease. <i>GastroHep</i> , 2021, 3, 212-228. | 0.3 | 7 |
| 7 | Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 692-695. | 1.0 | 1 |
| 8 | Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 542-556. | 0.6 | 50 |
| 9 | Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1551-1562. | 1.9 | 38 |
| 10 | Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. <i>Internal Medicine Journal</i> , 2020, 50, 798-804. | 0.5 | 12 |
| 11 | Editorial: balancing safety and efficacy "TGN thresholds in NUDT15 intermediate metabolisers treated with thiopurines. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 554-555. | 1.9 | 1 |
| 12 | A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1342-1352. | 1.9 | 11 |
| 13 | Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 612-628. | 1.9 | 49 |
| 14 | Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1527-1536. | 0.6 | 2 |
| 15 | Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy "early promise but more data needed. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 816-817. | 1.9 | 1 |
| 16 | Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 10-11. | 1.4 | 3 |
| 17 | Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481877278. | 1.4 | 38 |
| 18 | Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1135-1145. | 1.9 | 40 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Is there a role for thioguanine therapy in IBD in 2017 and beyond?. Expert Review of Gastroenterology and Hepatology, 2017, 11, 473-486. | 1.4 | 16 |
| 20 | Thioguanine in inflammatory bowel disease: Long-term efficacy and safety. United European Gastroenterology Journal, 2017, 5, 563-570. | 1.6 | 30 |
| 21 | Editorial: variability in adalimumab trough and peak serum concentrations – authors’ reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1476-1477. | 1.9 | 0 |
| 22 | Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Alimentary Pharmacology and Therapeutics, 2017, 46, 150-161. | 1.9 | 53 |
| 23 | Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2017, 46, 1037-1053. | 1.9 | 225 |
| 24 | Editorial: different tests for different drugs in Crohn’s disease, or different tests for different people? Authors’ reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 465-465. | 1.9 | 0 |
| 25 | Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn’s Disease. Inflammatory Bowel Diseases, 2017, 23, 1555-1565. | 0.9 | 21 |
| 26 | Therapeutic drug monitoring in inflammatory bowel disease: too little too early? – comments on the American Gastroenterology Association Guideline. Translational Gastroenterology and Hepatology, 2017, 2, 113-113. | 1.5 | 4 |
| 27 | PWE-013 – Should The Target TGN Range Be Different in Those with Intermediate Compared with Normal TPMT Activity?. Gut, 2016, 65, A143.2-A143. | 6.1 | 0 |
| 28 | Research topic: Managing compassionate therapy – the role of the virtual clinic. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 44-45. | 1.4 | 1 |
| 29 | Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn’s Disease. Inflammatory Bowel Diseases, 2015, 21, 2839-2847. | 0.9 | 42 |
| 30 | How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?. World Journal of Gastroenterology, 2015, 21, 11331. | 1.4 | 3 |
| 31 | PTU-076 – faecal calprotectin (FC) a reliable marker of isolated small bowel crohn’s disease (CD) activity?.. Gut, 2015, 64, A93.3-A94. | 6.1 | 0 |
| 32 | PTU-078 – A prospective evaluation of adalimumab drug levels and anti-drug antibodies using two commercial elisa and the influence of 6-thioguanine nucleotides amongst patients with inflammatory bowel disease:. Gut, 2015, 64, A95.1-A95. | 6.1 | 1 |
| 33 | PTU-077 – Association between crohn’s disease activity and therapeutic drug monitoring of thiopurines and infliximab comparing free and total antidrug antibody measurement: Abstract PTU-077 Table 1. Gut, 2015, 64, A94-A94. | 6.1 | 0 |
| 34 | Editorial: escalation to weekly dosing in adalimumab-treated patients with active ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2014, 40, 730-731. | 1.9 | 0 |
| 35 | The potential value of faecal lactoferrin as a screening test in hospitalized patients with diarrhoea. Internal Medicine Journal, 2010, 40, 819-827. | 0.5 | 7 |